TRANSGLIOMA faces the challenges identified by the EU2020 plan and the Italy-Slovenia Program. It is an implementation of the Interreg GLIOMA project, which discovered new cancer stem cell markers which will be used in a clinical environment for early diagnosis, response to treatment and as a therapeutic target. The innovative approach will allow single patients to receive a personalised treatment, contributing to an improvement in the quality of life of patients with brain tumours.